Andreas Wicki
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Oncology top 2%
- Lymphatic System and Diseases
- Cancer Cells and Metastasis
Papers in
- Oncology 36
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 6
-
- Melanoma and MAPK Pathways 6
- PI3K/AKT/mTOR signaling in cancer 6
- Co-authors
- Vimalkumar Balasubramanian (1 shared paper)Dominik Witzigmann (1 shared paper)Jörg Huwyler (1 shared paper)Gerhard Christofori (12 shared papers)François Lehembre (2 shared papers)Kenneth J. Clemetson (4 shared papers)Brigitte Hantusch (1 shared paper)Dontscho Kerjaschki (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)Blood (4 papers)Annals of Oncology (4 papers)International Journal of Cancer (3 papers)Clinical Cancer Research (3 papers)
- Partner nations
- SwitzerlandGermanyUnited States
In The Last Decade
Andreas Wicki
78 papers receiving 4.9k citations
Andreas Wicki's Hit Papers
Peers
Comparison fields: 5 of 141
- Biomaterials 1.2k
- Oncology 1.4k
- Hematology 414
- Cancer Research 399
- Molecular Biology 1.7k
Countries citing papers authored by Andreas Wicki
This map shows the geographic impact of Andreas Wicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Wicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Wicki more than expected).
Fields of papers citing papers by Andreas Wicki
This network shows the impact of papers produced by Andreas Wicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Wicki. The network helps show where Andreas Wicki may publish in the future.
Co-authors
The 25 scholars most cited alongside Andreas Wicki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications Hit paper breakdown → | 2014 | 1628 |
| 2 | 2006 | 496 | |
| 3 | 2006 | 256 | |
| 4 | Biology, vulnerabilities and clinical applications of circulating tumour cells Hit paper breakdown → | 2022 | 209 |
| 5 | 2012 | 208 | |
| 6 | 2016 | 169 | |
| 7 | 2008 | 159 | |
| 8 | [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. | 2006 | 155 |
| 9 | 2010 | 142 | |
| 10 | 1985 | 124 | |
| 11 | 1988 | 111 | |
| 12 | 2011 | 85 | |
| 13 | 2007 | 79 | |
| 14 | 2016 | 76 | |
| 15 | 2015 | 74 | |
| 16 | 1994 | 63 | |
| 17 | 2016 | 56 | |
| 18 | 1989 | 53 | |
| 19 | 1986 | 51 | |
| 20 | 2012 | 46 |
About Andreas Wicki
Andreas Wicki is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 88 papers that have together received 5.0k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (11 papers), Colorectal Cancer Treatments and Studies (8 papers), Platelet Disorders and Treatments (7 papers), Melanoma and MAPK Pathways (6 papers), Gastric Cancer Management and Outcomes (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Biomaterials (1.2k citations), Oncology (1.4k citations), Hematology (414 citations), Cancer Research (399 citations) and Molecular Biology (1.7k citations). Andreas Wicki has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Vimalkumar Balasubramanian, Dominik Witzigmann, Jörg Huwyler, Gerhard Christofori, François Lehembre, Kenneth J. Clemetson, Brigitte Hantusch, Dontscho Kerjaschki, Nikolaus Wick and Christoph Rochlitz. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, International Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.